By Richard Stern This e-mail was posted to the Health GAP Mailing List on March 29. It was a breath of fresh air to read Mark's piece ("Comments on Problems in the Current Draft World Health Organization (WHO) Antiretroviral Treatment…
HIV-Specific CD4 Cell, Holy Grail of Immune Control, Is Hunted Down in Paris Laboratory By Richard Jefferys "An Antibody Called IgG2" It's been five years since Bruce Walker and his Harvard colleagues first proposed the key role of CD4 T…
Merck's HIV Vaccine Program In a rapid-fire half-hour plenary session, Merck's head of HIV vaccine research Emilio Emini reviewed the company's development program and unveiled the first human immunogenicity data from phase I trials of their DNA and adenovirus type…
Activist Corpses Borne in Protest, Furtive Legislative Coups, and the Devastation That Was Berlin By Mark Harrington "We're Scientists Not Alchemists" Unlike clinical research in AIDS, basic research has not had a powerful constituency to advocate on its behalf. The…
A Peek Back at TAG's First Year Shows How Much, and How Little, Has Changed "Homing in on Basic Research" By Mark Harrington The beginning of this year marks TAG's tenth anniversary as the nation's only organization focused exclusively on…
Harvard Vaccine Team Exposes Potential Dark Side of Reliance on Cellular Immune Protection The Fate of Monkey #798 By Richard Jeffreys January 2002 proved to be a month of mixed blessings for the AIDS vaccine field. A slew of new…
Newly International North American Activist Alliance Gathers in Vancouver "Gathering Strength to Fight" By Mark Baker For the first time ever, NATAF (newly renamed from the National AIDS Treatment Activists Forum to the North American AIDS Treatment Action Forum) took…
On Friday, October 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead's nucleotide analogue reverse transcriptase inhibitor, tenofovir disoproxil fumarate (brand name, Viread). The labeling requested was for the "treatment of HIV-1 infection in combination with…
Reports of Progress Toward Understanding How Some People Appear to Fight Off HIV Identifying "Resistance" Epitopes By Richard Jeffreys In the United States, long-term studies of HIV-infected and high-risk people have mainly involved gay men -- the group most heavily…
Nongovernmental Organization Access Effort Dealt Stealth Blow By Ivy League Development Institute "We observe no apparent correlation between access to antiretroviral treatment, which is uniformly poor across Africa, and patent status, which varies extensively by country and drug." -- Amir Attaran,…